Skip to main content

Articles

Page 11 of 16

  1. Thrombosis and coagulopathy are the commonest hematological manifestations of envenomation of Russell’s viper venom (RVV). Factor X is activated by a factor X-activating enzyme from Russell’s viper venom (RVV-...

    Authors: Ren-Chieh Wu, Ping-Tse Chou and Li-Kuang Chen
    Citation: Thrombosis Journal 2016 14(Suppl 1):38

    This article is part of a Supplement: Volume 14 Supplement 1

  2. Platelets are central mediators of thrombosis and hemostasis. At the site of vascular injury, platelet accumulation (i.e. adhesion and aggregation) constitutes the first wave of hemostasis. Blood coagulation, ...

    Authors: Xiaohong Ruby Xu, Naadiya Carrim, Miguel Antonio Dias Neves, Thomas McKeown, Tyler W. Stratton, Rodrigo Matos Pinto Coelho, Xi Lei, Pingguo Chen, Jianhua Xu, Xiangrong Dai, Benjamin Xiaoyi Li and Heyu Ni
    Citation: Thrombosis Journal 2016 14(Suppl 1):29

    This article is part of a Supplement: Volume 14 Supplement 1

  3. Platelets play a key role in the pathophysiological processes of hemostasis and thrombus formation. However, platelet functions beyond thrombosis and hemostasis have been increasingly identified in recent year...

    Authors: Yukio Ozaki, Shogo Tamura and Katsue Suzuki-Inoue
    Citation: Thrombosis Journal 2016 14(Suppl 1):27

    This article is part of a Supplement: Volume 14 Supplement 1

  4. Venous thromboembolism (VTE), which constitutes pulmonary embolism and deep vein thrombosis, is a common disorder associated with significant morbidity and mortality. Landmark trials have shown that direct ora...

    Authors: Siavash Piran and Sam Schulman
    Citation: Thrombosis Journal 2016 14(Suppl 1):23

    This article is part of a Supplement: Volume 14 Supplement 1

  5. Hemophilia is the most well-known hereditary bleeding disorder, with an incidence of one in every 5000 to 30,000 males worldwide. The disease is treated by infusion of protein products on demand and as prophyl...

    Authors: Ching-Tzu Yen, Meng-Ni Fan, Yung-Li Yang, Sheng-Chieh Chou, I-Shing Yu and Shu-Wha Lin
    Citation: Thrombosis Journal 2016 14(Suppl 1):22

    This article is part of a Supplement: Volume 14 Supplement 1

  6. The antiphospholipid syndrome (APS) is an autoimmune disease characterised by a procoagulant state that predisposes to recurrent thrombosis and miscarriages. Two major discoveries have advanced our understandi...

    Authors: Fatima El-Assaad, Steven A. Krilis and Bill Giannakopoulos
    Citation: Thrombosis Journal 2016 14(Suppl 1):20

    This article is part of a Supplement: Volume 14 Supplement 1

  7. Snake venoms affect blood coagulation and platelet function in a complex manner. However, two classes of venom proteins, snaclecs and disintegrins have been shown to specifically target receptors including GPI...

    Authors: Tur-Fu Huang, Chun-Chieh Hsu and Yu-Ju Kuo
    Citation: Thrombosis Journal 2016 14(Suppl 1):18

    This article is part of a Supplement: Volume 14 Supplement 1

  8. Disseminated intravascular coagulation (DIC) is a serious disease that, in the presence of underlying disease, causes persistent, generalized, marked coagulation activation. Early treatment based on an appropr...

    Authors: Hidesaku Asakura, Hoyu Takahashi, Toshimasa Uchiyama, Yutaka Eguchi, Kohji Okamoto, Kazuo Kawasugi, Seiji Madoiwa and Hideo Wada
    Citation: Thrombosis Journal 2016 14:42
  9. We tested the hypothesis that disseminated intravascular coagulation (DIC) during the early phase of post-cardiopulmonary resuscitation (CPR) is associated with systemic inflammatory response syndrome (SIRS), ...

    Authors: Takeshi Wada, Satoshi Gando, Yuichi Ono, Kunihiko Maekawa, Kenichi Katabami, Mineji Hayakawa and Atsushi Sawamura
    Citation: Thrombosis Journal 2016 14:43
  10. Aortic thrombosis is a rare disease and only a few cases of the disease, especially associated with chemotherapy for malignant diseases and/or blood diseases, have been previously reported. Although Virchow’s ...

    Authors: Tomonori Sugiura, Yasuaki Dohi, Sumiyo Yamashita, Shunsuke Murai and Nobuyuki Ohte
    Citation: Thrombosis Journal 2016 14:16
  11. Vitamin K antagonists (VKAs) are effective oral anticoagulants that are titrated to a narrow therapeutic international normalized ratio (INR) range. We reviewed published literature assessing the impact of INR...

    Authors: Jeff R. Schein, C. Michael White, Winnie W. Nelson, Jeffrey Kluger, Elizabeth S. Mearns and Craig I. Coleman
    Citation: Thrombosis Journal 2016 14:14
  12. Guidelines from the Japanese Circulation Society recommend prophylaxis with anticoagulation plus intermittent pneumatic compression or graduated compression stockings (GCS) among patients at the highest risk f...

    Authors: Takeshi Fuji, Satoru Fujita, Tetsuya Kimura, Kei Ibusuki, Kenji Abe, Shintaro Tachibana and Mashio Nakamura
    Citation: Thrombosis Journal 2016 14:13
  13. The need for anticoagulation therapy (AC) in patients with subsegmental pulmonary embolism (SSPE) diagnosed by computed tomography of the pulmonary arteries (CTPA) has been questioned, as these patients run lo...

    Authors: R. Ghazvinian, A. Gottsäter and J. Elf
    Citation: Thrombosis Journal 2016 14:12
  14. Authors: Norikazu Yamada, Atsushi Hirayama, Hideaki Maeda, Satoru Sakagami, Hiroo Shikata, Martin H. Prins, Anthonie W. A. Lensing, Masaharu Kato, Junichi Onuma, Yuki Miyamoto, Kazuma Iekushi and Mariko Kajikawa
    Citation: Thrombosis Journal 2016 14:11

    The original article was published in Thrombosis Journal 2015 13:2

  15. Dabigatran etexilate may be underutilized in geriatric patients because of inadequate clinical experience in individuals with severe renal impairment and post-marketing reports of bleeding events. Assessing th...

    Authors: Luigi Brunetti, Betty Sanchez-Catanese, Leonid Kagan, Xia Wen, Min Liu, Brian Buckley, James P. Luyendyk and Lauren M. Aleksunes
    Citation: Thrombosis Journal 2016 14:10
  16. In hereditary spherocytosis with severe anemia, splenectomy is a recommended treatment. However, the spleen carries an important role both in immune function and coagulation. The increased risk of bacterial in...

    Authors: Cedric Davidsen, Terje Hjalmar Larsen, Eva Gerdts and Mai Tone Lønnebakken
    Citation: Thrombosis Journal 2016 14:9
  17. Thromboprophylaxis is recommended for patients undergoing total hip or total knee replacement (THR, TKR). An international, open-label, prospective, observational, single-arm study in a routine clinical settin...

    Authors: Nadia Rosencher, Charles M. Samama, Martin Feuring, Martina Brueckmann, Eva Kleine, Andreas Clemens and Simon Frostick
    Citation: Thrombosis Journal 2016 14:8
  18. Studies show the In-hospital Mortality for Pulmonary embolism using Claims daTa (IMPACT) rule can accurately identify pulmonary embolism (PE) patients at low-risk of early mortality in a retrospective setting ...

    Authors: Erin R. Weeda, Christine G. Kohn, Gregory J. Fermann, W. Frank Peacock, Christopher Tanner, Daniel McGrath, Concetta Crivera, Jeff R. Schein and Craig I. Coleman
    Citation: Thrombosis Journal 2016 14:7
  19. The Editors of Thrombosis Journal would like to thank all of our reviewers who have contributed to the journal in Volume 13 (2015) and whose valuable support is fundamental to its success.

    Authors: Hugo ten Cate and Yukio Ozaki
    Citation: Thrombosis Journal 2016 14:5
  20. Data estimating the annual incidence of venous thromboembolism (VTE) in France, taking into account both hospital and community settings, are very lacking.

    Authors: Stéphane Bouée, Corinne Emery, Adeline Samson, Julie Gourmelen, Cécile Bailly and François-Emery Cotté
    Citation: Thrombosis Journal 2016 14:4
  21. Despite the association of cancer-derived circulating tissue factor (TF)-containing microvesicles and hypercoagulable state, correlations with the incidence of thrombosis remain unclear.

    Authors: Camille Ettelaie, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John Greenman and Anthony Maraveyas
    Citation: Thrombosis Journal 2016 14:2
  22. Thus far, validated whole blood assays used in in vitro fibrinolysis experiments using thromboelastometry (ROTEM) are lacking or have yet to be tested in humans.

    Authors: Gerhardus J. A. J. M. Kuiper, Marie-Claire F. Kleinegris, René van Oerle, Henri M. H. Spronk, Marcus D. Lancé, Hugo ten Cate and Yvonne M. C. Henskens
    Citation: Thrombosis Journal 2016 14:1
  23. The aim of the study was to discuss the results of catheter-directed thrombolysis and complementary procedures to treat acute iliofemoral deep vein thrombosis (DVT) evaluating the safety and effectivness of an...

    Authors: Leslie Fiengo, Federico Bucci, Elias Khalil and Bruno Salvati
    Citation: Thrombosis Journal 2015 13:40
  24. Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not requir...

    Authors: Kazunori Otsui, Diana A. Gorog, Junichiro Yamamoto, Takayuki Yoshioka, Sachiyo Iwata, Atsushi Suzuki, Toru Ozawa, Asumi Takei and Nobutaka Inoue
    Citation: Thrombosis Journal 2015 13:39
  25. Although aspirin has a well-established role in preventing adverse events in patients with known cardiovascular disease (CVD), its benefit in patients without a history of CVD remains under scrutiny. Current d...

    Authors: Jobert Richie N. Nansseu and Jean Jacques N. Noubiap
    Citation: Thrombosis Journal 2015 13:38
  26. The aim of this study was to assess the safety and efficacy of switching therapy from low molecular weight heparin (LMWH; enoxaparin) to dabigatran for prevention of venous thromboembolic events (VTE) in patie...

    Authors: Christian Wurnig, Andreas Clemens, Helmuth Rauscher, Eva Kleine, Martin Feuring, Reinhard Windhager and Josef Grohs
    Citation: Thrombosis Journal 2015 13:37
  27. Two phase 3 trials compared 28–35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of venous ...

    Authors: Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher, Andreas Clemens, Stefan Hantel, Martin Feuring, Jörg Kreuzer, Michael Huo and Richard J. Friedman
    Citation: Thrombosis Journal 2015 13:36
  28. Venous thromboembolism (VTE) could be manifested as deep venous thrombosis (DVT) or pulmonary embolism (PE). DVT is usually the more common manifestation and is usually formation of a thrombus in the deep vein...

    Authors: Soudabeh Hosseini, Ebrahim Kalantar, Maryam Sadat Hosseini, Shadi Tabibian, Morteza Shamsizadeh and Akbar Dorgalaleh
    Citation: Thrombosis Journal 2015 13:35
  29. Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influenc...

    Authors: Giancarlo Agnelli, Anselm K. Gitt, Rupert Bauersachs, Eva-Maria Fronk, Petra Laeis, Patrick Mismetti, Manuel Monreal, Stefan N. Willich, Wolf-Peter Wolf and Alexander T. Cohen
    Citation: Thrombosis Journal 2015 13:41
  30. The aim was to assess the risk of venous thromboembolism (VTE) associated with use of combined oral contraceptives (COCs) in women with a family history of VTE.

    Authors: Bengt Zöller, Henrik Ohlsson, Jan Sundquist and Kristina Sundquist
    Citation: Thrombosis Journal 2015 13:34
  31. Deep vein thrombosis (DVT) and pulmonary emboli (PE), known together as venous thromboembolic (VTE) disease remain major complications following elective hip and knee surgery. This study compares three chemopr...

    Authors: Murray M. Bern, Diane Hazel, Elizabeth Deeran, John R. Richmond, Daniel M. Ward, Damon J. Spitz, David A. Mattingly, James V. Bono, Ronna H. Berezin, Laura Hou, Gerald B. Miley and Benjamin E. Bierbaum
    Citation: Thrombosis Journal 2015 13:32
  32. Platelet activation, thrombin generation and fibrin formation play important roles in intracoronary thrombus formation, which may lead to acute myocardial infarction.

    Authors: C. H. Hansen, V. Ritschel, S. Halvorsen, G. Ø. Andersen, R. Bjørnerheim, J. Eritsland, H. Arnesen and I. Seljeflot
    Citation: Thrombosis Journal 2015 13:31
  33. We report a case of unsuccessful percutaneous mechanical thrombectomy in treatment of a high-risk pulmonary embolism (PE). Pulmonary thromboemboli are commonly expected as a homogenous mass, rich with red bloo...

    Authors: Jernej Vidmar, Igor Serša, Eduard Kralj and Peter Popovič
    Citation: Thrombosis Journal 2015 13:30
  34. Dual antiplatelet therapy based on the combination of an adenosine diphosphate (ADP)-receptor antagonist plus aspirin has demonstrated to be more effective in reducing the rate of major ischemic vascular event...

    Authors: Hernan Polo Friz, Mauro Molteni and Claudio Cimminiello
    Citation: Thrombosis Journal 2015 13:28
  35. Atrial fibrillation (AF) puts patients at risk of complications, including stroke. Warfarin therapy has been the mainstay of antithrombotic treatment for reducing the risk of stroke in AF. However, warfarin ha...

    Authors: Alpesh Amin and Steven Deitelzweig
    Citation: Thrombosis Journal 2015 13:29
  36. In the absence of thromboprophylaxis, patients undergoing total hip arthroplasty (THA) are at increased risk for venous thromboembolism (VTE). The objective of this study was to compare the efficacy and safety...

    Authors: Takeshi Fuji, Satoru Fujita, Yohko Kawai, Mashio Nakamura, Tetsuya Kimura, Masayuki Fukuzawa, Kenji Abe and Shintaro Tachibana
    Citation: Thrombosis Journal 2015 13:27
  37. Although quantitative anti-FXa assays can be used to measure rivaroxaban plasma levels, they are not widely performed or available. We aimed to tentatively determine the cut-off for thromboembolism and bleedin...

    Authors: Raul Altman and Claudio Daniel Gonzalez
    Citation: Thrombosis Journal 2015 13:26
  38. A 43-year-old woman recipient of a bare metal coronary stent during an acute anterior myocardial infarction was repeatedly hospitalized with recurrent stent thrombosis (ST) over the following 3 years. Emergent...

    Authors: Takao Konishi, Tadashi Yamamoto, Naohiro Funayama, Beni Yamaguchi, Seiichiro Sakurai, Hiroshi Nishihara, Koko Yamazaki, Yusuke Kashiwagi, Yasuki Sasa, Mitsuru Gima, Hideichi Tanaka, Daisuke Hotta and Kenjiro Kikuchi
    Citation: Thrombosis Journal 2015 13:25
  39. Plasma phospholipid transfer protein (PLTP) transfers lipids between donors and acceptors (e.g., from HDL to VLDL) and modulates lipoprotein composition, size, and levels. No study has reported an assessment of t...

    Authors: Hiroshi Deguchi, Gertrud Wolfbauer, Marian C. Cheung, Yajnavalka Banerjee, Darlene J. Elias, José A. Fernández, John J. Albers and John H. Griffin
    Citation: Thrombosis Journal 2015 13:24
  40. The introduction of central venous catheters has advanced medical care, particularly in hemato-oncology. However these can be associated with an increased thrombotic risk. Previous studies have compared the ra...

    Authors: Priya Sriskandarajah, Katharine Webb, David Chisholm, Ravi Raobaikady, Kim Davis, Natalie Pepper, Mark E Ethell, Mike N Potter and Bronwen E Shaw
    Citation: Thrombosis Journal 2015 13:21
  41. Venous thromboembolism (VTE) is a burden on healthcare systems. Standard treatment involves parenteral anticoagulation overlapping with a vitamin K antagonist, an approach that is effective but associated with...

    Authors: Luke Bamber, Dominic Muston, Euan McLeod, Anne Guillermin, Julia Lowin and Raj Patel
    Citation: Thrombosis Journal 2015 13:20
  42. The clinical picture of deep vein thrombosis (DVT) is nonspecific. Therefore assessment of the probability of occurrence of DVT plays a very important part in making a correct diagnosis of DVT.

    Authors: Małgorzata Dybowska, Witold Z Tomkowski, Paweł Kuca, Rafał Ubysz, Adam Jóźwik and Dariusz Chmielewski
    Citation: Thrombosis Journal 2015 13:18
  43. Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for the prevention and treatment of venous thromboembolism and for stroke prevention in patients with atrial fibrillation. NOACs do no...

    Authors: Hein Heidbuchel, Dana Berti, Manuel Campos, Lien Desteghe, Ana Parente Freixo, António Robalo Nunes, Vanessa Roldán, Vincenzo Toschi and Riitta Lassila
    Citation: Thrombosis Journal 2015 13:22
  44. Autoinflammatory diseases are a group of disorders due to acquired or hereditary disfunction of innate immune system and characterized by systemic or localized manifestations. The prototype is Familial Mediter...

    Authors: Micaela La Regina, Francesco Orlandini and Raffaele Manna
    Citation: Thrombosis Journal 2015 13:19

Official journal of

  • Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.

Annual Journal Metrics

  • 2022 Citation Impact
    3.1 - 2-year Impact Factor
    3.8 - 5-year Impact Factor
    1.011 - SNIP (Source Normalized Impact per Paper)
    0.699 - SJR (SCImago Journal Rank)

    2023 Speed
    10 days submission to first editorial decision for all manuscripts (Median)
    107 days submission to accept (Median)

    2023 Usage 
    708,004 downloads
    943 Altmetric mentions